)
Visual
earnings real time
Outlook Therapeutics (OTLK) investor relations material
Outlook Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Dec, 2025
Executive summary
Fiscal 2025 net loss attributable to common stockholders was $62.4 million, or $1.79 per share, on $1.4 million in revenue, compared to a $75.4 million net loss and no revenue in the prior year.
Initial commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK began in June 2025, with growing account and clinician adoption into early fiscal 2026.
Awaiting FDA decision for U.S. approval of ONS-5010/LYTENAVA™, with a PDUFA goal date of December 31, 2025.
Financial highlights
Revenue for fiscal 2025 was $1.4 million, reflecting first sales in Germany and the UK; no revenue was reported in fiscal 2024.
Net loss improved to $62.4 million from $75.4 million year-over-year.
Gross profit was negatively impacted by increased reserves for short-dated inventory in the UK.
R&D expenses decreased significantly due to completion of the NORSE Eight clinical trial, partially offset by higher SG&A expenses for the European launch.
Cash and cash equivalents at September 30, 2025, were $8.1 million, not including $14.9 million in net proceeds from an at-the-market offering after year-end.
Outlook and guidance
Preparing for potential U.S. commercial launch pending FDA approval, with ongoing expansion efforts in Europe, including Austria and the Netherlands.
LYTENAVA™ accepted into the UK tender framework in December 2025 and a real-world data study initiated in Germany.
Continued focus on expanding market access and pricing at national and sub-national levels in Europe.
US launch preparations post-FDA decision
Impact of short-dated inventory on EU sales
Cash runway with planned US/EU expansion
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Outlook Therapeutics earnings date
Q1 202613 Feb, 2026
Next Outlook Therapeutics earnings date
Q1 202613 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and launching innovative treatments for ocular diseases. The company is currently working on ONS-5010 / LYTENAVA™ (bevacizumab-vikg), aiming to make it the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The company is headquartered in Iselin, New Jersey, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage